You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Stay informed

Live Chat

Avamys nasal spray

Avamys nasal spray is indicated for the treatment of the symptoms of allergic rhinitis in adults, adolescents and children (aged 6 and over). 1

Avamys Indications

Avamys device stays where it sprays

Find out more
Indication Efficacy

Indications and Efficacy

Targeted action with Avamys

Find out about tissue retention and receptor affinity of fluticasone propionate.

Find out more
Guidlines

Guidelines

Guideline recommendations

INCS is recommended by various guidelines for allergic rhinitis.
2910

Read more

Easy-to-use device

Dosage & device

A patient-friendly, easy-to-use device

Avamys is delivered via a patient-friendly, easy-to-use device that patients prefer. 4-8

Read more

References:

  1. Avamys Summary of product Characteristics Available from www.medicines.ie (https://www.medicines.ie/medicines/avamys-27-5-micrograms-spray-nasal-spray-suspension-31374/) last accessed November 2023
  2. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug deliver device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4(6):689-701.
  3. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313-321.
  4. Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958.
  5. Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Head Neck Surg. 2015:152(18) S1-S43.
  6. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2017;47:856-889.
  7. Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017;167(12):876-881.
  8. Santos A, Borrego LM, Rotiroti G, et al. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015;5:2.
  9. Berger WE, Godfrey JW, Grant AC, et al. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. J Allergy Clin Immunol. 2007;119:S231.
  10. Godfrey JW, Grant AC, Slater AL. Fluticasone Furoate (FF) Nasal spray-ergonomic considerations for a next generation delivery system. J Allergy Clin lmmunol. 2007;119(Suppl. 1):S230.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Avamys is a registered trademark of the GlaxoSmithKline group of companies